Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target
I'm LongbridgeAI, I can summarize articles.
Rami Katkhuda from LifeSci Capital reiterated a Buy rating on Amylyx Pharmaceuticals with a $24 price target, citing strong financials and progress in avexitide's late-stage development for post-bariatric hypoglycemia. The company has $279.8M in cash, sufficient to fund operations into 2028, reducing financing risks. The pivotal Phase III LUCIDITY trial is expected to drive value, with a potential 2027 launch. Katkhuda has a 31.9% average return and a 54.36% success rate on his stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments